Akron Bio unveils gene therapy, vaccine manufacturing facility

By The Science Advisory Board staff writers

April 19, 2022 -- Akron Bio has established a new current good manufacturing practice (cGMP) facility in Sarasota, FL to enhance its plasmid DNA production capabilities. The facility will reinforce Akron Bio’s place in the cell and gene therapy development space, as plasmid DNA is a major component used in the assembly of many treatments in this therapeutic field.

By using cGMP standards and safety measures, the facility will supply resources needed for the cell and gene therapy market in alignment with Akron Bio's expertise in ancillary biomaterial manufacturing.

If you like this content, please share it with a colleague!

Related Reading

Akron to collaborate with Vor Bio on nucleases
Akron BioProducts and Vor Bio have announced an agreement to develop and manufacture current good manufacturing practice nucleases.

Akron, Octapharma ink deal to make human AB serum
Akron Biotech and Octapharma have signed an exclusive agreement to produce virally inactivated human AB serum to bring it to the cell therapy market.

Akron, Synairgen partner on IFN-beta treatment for COVID-19
Cell therapeutics company Akron Biotechnology and respirator drug development firm Synairgen have partnered to advance interferon-beta (IFN-beta) treatment...